Coming up: European Drug Report 2016

Latest annual trends from the EMCDDA

Banner advertising 2016 EDR

What are the latest trends in drug supply to Europe? What drugs are causing the most harm and concern today? What are the most recent developments in drug prevention, treatment and policy?  These and other questions will be explored by the EU drugs agency (EMCDDA) on 31 May in its annual overview of the European drug situation.

The European Drug Report 2016: Trends and Developments, provides a comprehensive analysis of the latest tendencies across the 28 EU Member States, Turkey and Norway. In print and pdf in 24 languages, the report examines: drug supply and the market; drug use prevalence and trends; and drug-related health problems and responses to them.

Accompanying the report will be Perspectives on Drugs (PODs), online interactive insights into specific issues in the drugs field. Among the themes in focus this year are: changes in Europe’s cannabis resin market; cocaine trafficking to Europe; strategies to prevent the diversion of opioid substitution treatment medications; and co-morbidity of substance use and mental health disorders.

The information package will be completed by the 2016 Statistical Bulletin, containing the full European dataset underpinning the report, and Country Overviews, providing national-level data and analyses.  An e-publication (English) and audiovisual material will also be available.  

Launch details

Date: 31 May 2016

Time: 10:00 Western European Time (Lisbon) (11:00 Central European Time)

Venue: Conference Centre, Praça Europa 4, Cais do Sodré, 1249-206, Lisbon

Press conference: In the presence of Dimitris Avramopoulos, European Commissioner responsible for Migration, Home Affairs and Citizenship; Laura d’Arrigo, Chair of the EMCDDA Management Board and Alexis Goosdeel, EMCDDA Director.

Interviews: EMCDDA representatives will be available on the day of the launch in Lisbon to answer journalists’ questions (details available via the link below). Across Europe, staff at the Reitox national focal points will answer country-specific queries (please consult our Helpdesk list).

Find out more: